Human immunodefi ciency virus (HIV) has huge health, social and economic impacts. Current therapies can control the infection but a true cure or effective vaccine has yet to be found. To achieve these objectives, one must take into consideration the great genetic variability and rapid evolution of HIV. These special characteristics can be associated, for example, with antigenic changes and the emergence of drug-resistant variants.
■ WHAT IS HIV AND WHAT IS ITS SIGNIFICANCE?
Acquired immune defi ciency syndrome (AIDS) is a global public health problem. Since its discovery in 1983, the human immunodefi ciency virus (HIV) has killed about 30 million people and more than 40 million people are infected, most in developing countries. The human immunodefi ciency virus is a retrovirus that specifi cally infects immune system cells expressing the membrane receptor CD4, mainly T4 lymphocytes. As a result, the virus causes gradual weakening of the immune system. In advanced stages, the infection causes the appearance of opportunistic diseases and cancers characteristic of AIDS. Without treatment, death occurs on average about 10 years after infection. However, there is great variability in the progression time of the disease, depending on the characteristics of the virus and the patient's immune system.
The study of the evolution of HIV has shed light not only on its natural history but also on its pathogenesis mechanisms. Through evolutionary studies we can attempt to predict, for example, how the virus might respond to the presence of drugs or which variants are more likely to spread in the future. In fact, evolutionary studies have long had a positive impact on the design of treatments for human disease in general. For example, estimates for the mutation rate (probability of changes in genetic material) of HIV and hepatitis C have shown that all possible changes in a single nucleotide occur daily inside a patient. Therefore, drug resistance is almost inevitable unless a combination of therapies is used, each with different targets, and thus requiring multiple genetic changes in the virus for it to develop resistance to the treatment.
■ ORIGINS AND EPIDEMIOLOGY
Studies on variability and evolution of HIV have shown us that there are two types, HIV-1 and HIV-2, with different geographical origin and related to different simian immunodefi ciency viruses (SIV). Both originated as the result of zoonosis, that is, transmission of a disease from animals to humans. HIV-1 originated in chimpanzees after one or more recombination events between different SIV, allowing the disease to jump the species barrier due to environmental or genetic factors (Gao et al., 1999) . On the other hand, HIV-2 probably originates from the VIS of the grey mangabe. HIV-1 causes most infections and is the more virulent of the two types. The divergence observed in the whole genome between HIV-1 and HIV-2 is approximately 40% to 60%. Between different subtypes of HIV-1, divergence can be up to 35%, while in the so-called M group (which causes 95% of HIV infections) it is estimated between 10% and 30%. The highest divergence values have been observed in the gene which codes for the envelope (env) (Brenner, 2007) . Figure 1 shows the abundance of the different genotypes of HIV-1 in the world and an example of diversity in the env gene between the different genotypes of HIV-1.
Epidemiology is devoted to studying the causes, incidence, distribution and control of diseases in human populations. From a practical point of view it is important to consider both the epidemic process and the evolution of pathogens, whether related to the evolution of drug resistance or virulence of the pathogen, vaccine design, or the emergence of new pathogens and diseases. Understanding how a pathogen can successfully invade and spread in the population is of paramount interest. The 2010 UNAIDS report showed that new HIV infections have been declining since the late 90s in most of the affected countries in sub-Saharan Africa, due to preventive measures like the use of condoms. Conversely, in some countries in Eastern Europe and Central Asia, HIV incidence has increased. The report also showed how increased access to treatment has resulted in a signifi cant decrease in deaths from HIV, and how vertical transmission from mother to child can be virtually eliminated if treatment is applied in the fi rst weeks of pregnancy.
■ EVOLUTIONARY MECHANISMS
Mutation creates new genetic variability, while recombination, broadly defi ned, produces high genetic variability. Deterministic factors (such as mutation, migration or selection) or random factors (such as genetic drift) can act on this genetic variability. Some viruses use RNA as genetic material instead of DNA, and the former are characterized by particularly high mutation rates. This is the case of HIV, which uses a special polymerase to replicate its genome. This polymerase is called reverse transcriptase, and it copies RNA to make DNA. Most polymerases that use RNA as a template lack error correction mechanisms and this leads to mutations, which favour viral populations with high genetic variability. Figure 2 shows how mutation rates vary in different organisms. The highest mutation rate was described in a plant viroid. Within the virus group, RNA viruses have the highest mutation rates, followed by single strand DNA (ssDNA) viruses and double stranded DNA viruses. The mutation rate of HIV is within the range typical for RNA viruses. Organisms with a cellular structure have mutation rates about 100,000 times lower than those of RNA viruses. Another very important aspect in the evolution of HIV is recombination. The HIV virion possesses two genome copies as RNA and the reverse transcriptase can jump from one strand to another during DNA synthesis, resulting in recombinant molecules (Simon-Lorière and Holmes, 2011). Recombination played a key role in the origins of HIV and could result in a new type of HIV in the future. Recombination affects host range expansion, virus virulence, immune system evasion or acquisition of drug resistance. For example, the circulating recombinant form 01_AE, once settled in northern 
Thailand, increased its frequency and quickly dominated the rest of Thailand, Laos, Cambodia and Vietnam (Stephens, 2005) . Genetic drift is the process by which allele frequencies change randomly from one generation to the next due to sampling effects in populations. The smaller the population size the greater its intensity, and in the case of HIV, it occurs mainly in the transmission between people, because it entails bottlenecks in the viral population size. There is consensus that HIV infection usually begins with the transmission of one or a few infectious particles (Keele et al., 2008) . Bottlenecks may also occur in the patient, for example in tissue subdivisions. On the other hand, natural selection causes changes in allele frequencies by acting on mutations or genomes that infl uence biological effi ciency. Selection may be adaptive or positive when it promotes the fi xation of mutations that are benefi cial in a given environment or negative when deleterious mutations are eliminated. Both the host's immune system and antiviral treatments exert strong selection pressures on the virus, as discussed below. Evolutionary mechanisms acting on viral populations may have a different role in the host and between hosts. For example, when observing the phylogenetic relationships of viral variants for the env gene encoding the viral envelope, one can distinguish two different patterns. On the one hand, intra-host phylogenies indicate the importance of the action of selection pressures while, on the other, inter-host phylogenetic trees suggest that genetic drift plays a greater role (Grenfell et al., 2004) (Figure 3 ). 
«RECOMBINATION PLAYED A VERY IMPORTANT PART IN THE ORIGIN OF HIV AND COULD LEAD TO A NEW TYPE OF HIV IN THE FUTURE»
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MONOGRAPH ■ ESCAPING THE IMMUNE SYSTEM
The host's immune system has an innate component (non-specifi c) and another adaptive component (specifi c). The innate immune response is characterized by fever, infl ammation and other symptoms, which are controlled by processes such as cytokine secretion (e.g., interferon). In the case of HIV, the enzyme APOBEC3G (a protein that edits single-stranded DNA) is involved in the innate immune response and causes mutations that inactivate the virus during the process of viral DNA synthesis from RNA. To counteract the effect, HIV incorporated a gene into its genome called viral infectivity factor (vif) (Kirchhoff, 2010) . In the case of specifi c or adaptive immune response in vertebrates, there are a number of genes coding for the major histocompatibility complex (MHC). This complex presents portions of viral proteins called epitopes, allowing the launch of an immune response against the virus. Human populations are extraordinarily variable for MHC genes and therefore recognize different viral epitopes. Some MHC variants have been shown to respond better to infection than others, and thus are associated with a slower progression of the disease (Buckheit III et al., 2012) . In order to understand this, it becomes necessary to consider the evolution of HIV within patients. The pressure exerted by specifi c immune responses selects for viral mutants able to evade this response. However, these mutations may compromise the ability of the virus to carry out its infectious cycle, if the mutations happen to affect important regions of the viral proteins (conserved regions). Precisely those variants capable of recognizing viral epitopes in conserved regions are the ones associated with a better prognosis.
■ ANTIVIRAL RESISTANCE
Because viruses are obligate intracellular parasites and use the cellular machinery, it is diffi cult to fi nd compounds that only affect viral activity, because they can also adversely affect the host cell. Therefore, an essential approach to the design of new drugs is to identify the specifi c steps of the viral infectious cycle. The reverse transcriptase and the protease responsible for processing the polyprotein encoded by HIV are ideal targets, as they are unique to the virus. The fi rst compound that showed effectiveness against the reverse transcriptase was azidothymidine (AZT), a nucleoside analogue whose structure is similar to that of the nucleotides that make up DNA. When AZT is present in the cell, the reverse transcriptase erroneously adds it to the newly synthesized DNA strand and interrupts synthesis (Figure 4 ). However, it was observed that after one or two years of treatment, HIV patients became unresponsive and the disease continued its progression. The resistance was due to mutations in the reverse transcriptase gene, which were convergent, meaning that they appeared in viral populations from different patients. To date, some of the mutations described are located in the active site of reverse transcriptase, and are named L74V and T215Y (nomenclature indicates the amino acid change, and the position in which it occurs) (Bennett et al., 2009) (Table 1) . Importantly, some mutations cause cross-resistance to other antiviral nucleoside analogues (Margeridon-Thermet and Shafer, 2010). Thus, the genetic composition of the HIV population changed over time in response to the presence of AZT. This is a clear example of evolution by natural selection. Consequently, the current treatment involves combinations of three or four drugs, including reverse transcriptase and protease inhibitors. This combination therapy is very effective at blocking virus replication and reducing viral load in the blood. However, as the virus is latent in some cells, the blockade is not complete, potentially allowing resistant viral particles to appear, preventing the eradication of the virus. 
■ VACCINE DESIGN
Vaccines induce a specifi c cellular and humoral immune response, so that the vaccinated individual develops an "immune memory" which gives a better chance in fi ghting off the pathogen. Traditionally different strategies have been used, such as inactivated pathogens (by heat or chemically), attenuated pathogens or administration of surface compounds that act as antigenic determinants, recognized by the immune system's cells. Vaccination has had great success in the prevention and control of various diseases such as polio, smallpox, measles, rubella or fl u. However, we have yet to see effective vaccines developed against HIV-1 or hepatitis C. One of the diffi culties faced in developing a vaccine against HIV-1 is the high genetic variability and rapid evolution of the virus. As a consequence of this large variability, especially in the gene encoding the envelope protein, a vaccine that protects against a particular subtype may not grant, or grant only partial protection against other subtypes. However, epidemiological studies report that a low effi cacy vaccine may reduce the incidence of HIV-1 by a signifi cant percentage (UNAIDS, 2010) . In this area, we highlight the study conducted in 2009 on the Thai population. The results of phase III clinical trials showed a 30% effi cacy in protecting against HIV. The vaccine consisted of a combination of a vector expressing HIV-1 immunogens (substances that induce the adaptive immune response) and a recombinant version of the envelope protein (Rerks-Ngarm et al., 2009) . Although this result does not provide suffi cient evidence to back the general distribution of the vaccine, it gives clues about where further research should aim in order to enhance the immune response. New research should aim towards creating new constructions, use of multiple doses or even the administration of more and better adjuvants (immune response enhancers) that might be supplied along with it.
Increased access to treatment has resulted in a signifi cant decrease in deaths from HIV. Above, a sign in Zambia reminds the population about the importance of testing themselves for HIV.
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■ CONCLUSIONS AND FUTURE PROSPECTS
Well aware of the importance of AIDS, many funds have been allocated to the study of HIV. The main objectives of the research groups engaged in these endeavours are to fi nd effective antiviral drugs and a vaccine. The fi rst objective has been largely fulfi lled. However, obtaining an effective vaccine seems a goal on a distant horizon. The high genetic variability of HIV, due to its high mutation and recombination rates, along with the characteristic latent infection of the disease, makes it especially diffi cult to combat. Thus, knowledge and understanding of the evolutionary mechanisms that govern the evolution of HIV are key not only to the secrets of how the disease originated, but also how it develops, how to treat it, how it might change in the future and, ideally, how to eradicate it.
